3 days Ago By ABMN Staff
Taysha Gene Therapies ( NASDAQ:TSHA – Free Report ) had its target price hoisted by Canaccord Genuity Group from $6.00 to $8.00 in a research report report published on Friday, Benzinga reports.
They currently have a buy rating on the stock. Other research analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.
00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th.
Chardan Capital reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.
00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $6.
63. Check Out Our Latest Stock Report on Taysha Gene Therapies Taysha Gene Therapies Price Performance Hedge Funds Weigh In On Taysha Gene Therapies Several institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 328.
2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after buying an additional 14,294,445 shares during the last quarter. Artal Group S.
A. lifted its holdings in Taysha Gene Therapies by 0.7% in the 1st quarter.
Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after purchasing an additional 24,444 shares during the last quarter.
Geode Capital Management LLC increased its position in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period.
State Street Corp increased its position in Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after buying an additional 150,647 shares during the period.
Finally, StemPoint Capital LP bought a new stake in shares of Taysha Gene Therapies during the first quarter valued at approximately $3,122,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.
Taysha Gene Therapies Company Profile ( Get Free Report ) Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Featured Stories Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.
com's FREE daily email newsletter ..
